Evan Jones, Chairman and CEO
Mr. Jones is the Chairman and CEO of OpGen and also is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute.
Mr. Jones received a B.A. degree from the University of Colorado and an M.B.A. from The Wharton School, University of Pennsylvania.
Timothy Dec, Chief Financial Officer
Mr. Dec, has more than 20 years of public company financial leadership experience in technology and healthcare companies. He has served in chief financial officer or other senior financial executive roles at companies in a number of industries, including three publicly traded companies listed on NASDAQ or AMEX, such as Corvis Corporation, and at private equity-backed companies. Prior to joining OpGen, Mr. Dec served as Senior Vice President and Chief Financial Officer for Clubwidesports, LLC, a start-up sports management software company, from January 2014 to April 2015. From August 2007 to December 2012, He was Senior Vice President and Chief Financial Officer of Fortress International Group, Inc., a publicly traded company. Mr. Dec also has public accounting firm experience. He is an adjunct professor at Mount St. Mary’s University in Emmitsburg, Maryland, where he teaches M.B.A. courses in Finance.
Mr. Dec holds a B.S. in accounting from Mount Saint Mary’s University, and an M.B.A. from American University in Washington, DC.
Robert McG. Lilley, Chief Commercial Officer
Mr. Lilley joined OpGen in October 2014 as Chief Commercial Officer. Mr. Lilley is currently non‑executive Chairman of the Board of Directors of Immunexpress, Inc., a Seattle-based molecular diagnostic company focused on developing diagnostic tests for patients at risk of sepsis. He previously served as Senior Vice President, Global Sales and Marketing for Digene Corporation, from June 1999 until its sale to QIAGEN NV in 2007. He had held prior sales executive positions with Digene from March 1997 to June 1999. Mr. Lilley worked for QIAGEN NV as Senior Advisor, Molecular Diagnostics from August 2007 until September 2009. He previously served as Head of Europe, Middle East, and Africa (EMEA) Sales and Marketing for TDS Healthcare Information Systems, as well as Senior Vice President and General Manager EMEA of Alltel Healthcare Systems.
In 1970, Mr. Lilley joined the first Earth Day team, and he has retained an interest in environmental affairs since. Today he serves on the Boards of the Global Footprint Network, and Terra Global Capital, both based in the San Francisco Bay Area. He has also served on the Board of Trustees of The Center for Advanced Studies in the Behavioral Sciences (CASBS) at Stanford University.
Mr. Lilley holds a BA from Yale University.
Vadim Sapiro, Chief Information Officer
Mr. Sapiro joined OpGen in December, 2011 with responsibility for leading the development of the Company’s bioinformatics applications, software, databases and information technology operations. Prior to OpGen, he was senior vice president at SAIC-Frederick overseeing the Information Systems Program for the National Cancer Institute at Frederick with responsibility for information technology, scientific computing and bioinformatics. Among his projects were technical program management and operations for the cancer Biomedical Informatics Grid (caBIG™), the cancer Human Biobank (caHUB) and The Cancer Genome Atlas (TCGA). Prior to SAIC, Mr. Sapiro was vice president for information technology with the J. Craig Venter Institute. He is active in the regional and national technology and research communities, having served on many life sciences and biotech focused advisory boards and review committees.
Mr. Sapiro holds a B.S. in Mathematics and Computer Science from the University of Maryland.
Geoffrey A. McKinley, Ph.D., Sr. VP, Research & Development and Business Development
Dr. McKinley joined OpGen in July 2015 when OpGen acquired AdvanDx, Inc. At AdvanDx, he was Senior Vice President of R&D and Business Development responsible for R&D strategy and new product development plan. Role included project responsibility including R&D, Program Management, Quality, Regulatory and Intellectual Property. Prior to AdvanDx, he was Chief Science Officer at DxNA, Inc. focused on infectious disease sample to answer product development, intellectual property and business partnering. Dr. McKinley was Senior Vice President of Research & Development at GenturaDx, Inc. prior to DxNA and lead the development of the IDbox integrated sample-to-answer system enabling Gentura’s acquisition by Luminex Corporation (NASDAQ;LMNX)in 2012. Osmetech plc (LSE:OMH) (currently GenMark Diagnostics, Inc. NASDAQ:GNMK) in 2004 and served as Vice President of Molecular Diagnostics Research & Development and Business Development and Direct of Ohmx Corporation where he participated in the dollar acquisitions of Molecular Sensing, plc and Clinical Micro Sensors and led the launch of the electrochemistry-based XT-8 multiplexed detection system. From 2002 to 2004, he served as Vice President of R&D and Business Development for Naxcor, Inc. From 1994 to 2002 Dr. McKinley held various positions with bioMérieux, Inc. (EPA:BIM). He served as Molecular Diagnostic Project Leader/Director of Research & Development from 1994 to 2000 with global molecular diagnostic systems development responsibility and Senior Director of Business and Technology at bioMérieux from 2000 to 2002 with responsibility for new technologies including its molecular biology business. He started his career with Analytab Products, Inc. (which was held by American Home Products / Wyeth Pharmaceuticals) where he held various positions including Vice President, Research & Development.
Dr. McKinley is an author on 12 U.S. patents and received his Ph.D. from Colorado State University.
Charles Thornton, M.B.A., Ph.D., RAC
Vice President, Quality Assurance and Regulatory Affairs
Dr. Thornton, is the Vice President, Quality Assurance and Regulatory Affairs for OpGen’s clinical laboratory operations in Gaithersburg, MD, and the medical device manufacturing facility in Woburn. MA. He has over 25 years of industry and US Food and Drug Administration (FDA) experience, including extensive experience in in vitro diagnostics (IVD). He has designed and implemented Laboratory Developed Tests (LTDs) for the clinical laboratory, developed Good Clinical Practice (GCP) and Design Control quality systems for manufacturers, and designed, implemented, and managed clinical trials to generate data for regulatory submissions. Dr. Thornton previously served as a Scientific Reviewer within FDA’s Office of In Vitro Diagnostics and Radiological Health (OIR), and as a Reviewer within FDA’s Office of Compliance (OC), Division of Bioresearch Monitoring (BIMO).
Dr. Thornton received a B.S. in Biochemistry from the State University of New York at Stony Brook, an M.B.A. from George Washington University, and a Ph.D. in Biochemistry and Molecular Biology from Case Western Reserve University. He has a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).
Terry Walker, Ph.D., Sr. VP, Research & Development
Dr. Walker’s responsibilities include leading the development of genomic technologies and new products supporting molecular diagnostics for infectious diseases. Prior to OpGen, He previously led drug target validation, biomarker discovery and clinical diagnostic development at Pfizer, GlaxoSmithKline (GSK), Becton Dickinson (BD), Duke University and The Biomarker Factory across most disease areas and stages of development from discovery through late clinical trials.
Dr. Walker received his Ph.D. in Biophysical Chemistry from the University of Rochester with postdoctoral training in Biophysical Chemistry at the University of California, Berkeley.